- Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the Food and Drug Administration, 1998–2005. Arch Intern Med 2007;167 (16): 1752–1759.
- US Food and Drug Administration. The Challenge to Improve Patient Safety: FDA Logs Over 350,000 Reports of Adverse Events Annually [Just the Facts Series, Publication No. FS 01-9]. Rockville, MD: Food and Drug Administration, revised February 2002.
- Strom BL. How the US drug safety system should be changed. JAMA 2006;295 (17): 2072–2075 (citing Bakke OM, Manocchia M, de Abajo F, Kaitin KI, Lasagna L. Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective. Clin Pharmacol Ther 1995;58 (1): 108–117).
- Strom BL. How the US drug safety system should be changed. JAMA 2006;295 (17): 2072–2075 (citing Leape LL, Brennan TA, Laird N, Lawthers AG, Localio AR, Barnes BA, Hebert L, Newhouse JP, Weiler PC, Hiatt H. The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N Engl J Med 1991;324 (6): 377–384).
- See, e.g., McNeil v Wyeth, 462 F2d 364 (5th Cir 2006); Chandler v Simpson, 100 Wash App 1034, 2000 WL 426441 (Wash App Div 3 Apr 18, 2000); Gatling v Perna, 788 SW2d 44 (Tex App—Dallas 1990) (writ denied).
- See, English v General Electric Co, 496 US 72, 78–79 (1990); Erie v Thompkins, 304 US 64 (1938).
- See, In re: Vioxx Products Liability Litigation, — FSupp2d —, 2007 WL 1952964, *9 (ED La July 3, 2007) (citing Wack v Lederle Labs, 666 FSupp 123, 128 [ND Ohio 1987] and Rabin RL. Poking holes in the fabric of tort: a comment. DePaul Law Review 2007;56: 293).
- See, Hill v Searle Laboratories, 884 F2d 1064, 1068 (8th Cir 1989); Osburn v Anchor Laboratories, Inc, 825 F2d 908, 912–913 (5th Cir 1987); Wells v Ortho Pharm Corp, 788 F2d 741, 746 (11th Cir 1986).
- Buckman v Plaintiff's Legal Committee, 531 US 1012 (2001).
- Avorn J, Shrank W. Highlights and a hidden hazard—the FDA's new labeling regulations. N Engl J Med 2006;354 (23): 2409–2411.
- Rauschenberger SJ. Re: Food and Drug Administration Final Rule on the Requirements on Content and Format of Labeling for Human Prescription Drug and Biologic Products; Requirements for Prescription Drug Labels, Docket No. 00N-1269 [letter to Mike Leavitt, Secretary, US Department of Health and Human Services], January 13, 2006. Available at http://www.ncsl.org/programs/press/2006/060113Leavitt.htm; accessed July 20, 2007.
- Ruby Ledbetter v Merck & Co, Inc, 2007 WL 1181991, *1181991+(Trial Order) (Tex Dist Apr 19, 2007) Order Granting Defendant's Motion for Partial Summary Judgment and Granting Expedited Appeal (No 2005-59499).
- See, Cooper RB, Faust DL. Products liability after House Bill 4. South Texas Law Review 2005;46: 1159, 1175.
- Warner-Lambert v Kent, — SCt —, 2007 WL 1420397 (US), 75 USLW 3923 (Sep 25, 2007).
- Riegel v Medtronic, Inc, — SCt —, 2007 WL 1802109 (US), 75 USLW 3065 (June 25, 2007).
- See, In re: Vioxx Products Liability Litigation, — FSupp2d —, 2007 WL 1952964 *11, n.6 (ED La July 3, 2007).
- Desiano v Warner-Lambert & Co, 467 F3d 85 (2nd Cir 2007).
- Mich Comp Laws, §600.2945(5).
- Tex Civ Prac & Rem Code, §82.007 (Vernon's 2007).
- Michigan House Democrats. House votes to end drug industry immunity: Bills holding drug companies accountable head to Senate [press release, February 23, 2007]. Available at http://www.housedems.com/news/article/drug-industry; accessed October 3, 2007.
- US Food and Drug Administration. Law strengthens FDA. Available at http://www.fda.gov/oc/initiatives/advance/fdaaa.html; accessed October 3, 2007.
- Psaty BM, Burke SP. Protecting the health of the public—Institute of Medicine recommendations on drug safety. N Engl J Med 2006;355 (17): 1753–1755.
- Psaty BM, Charo RA. FDA responds to Institute of Medicine drug safety recommendations—in part. JAMA 2007;297 (17): 1917–1920.
- Slater EE. Today's FDA. N Engl J Med 2005;352 (3): 293–297.
- Okie S. What ails the FDA? N Engl J Med 2005;352 (11): 1063–1066.
- Boulding ME. The statutory basis for FDA regulation of scientific and educational information. Journal of Pharmacy and Law 1995;4 (2): 123–142.
- US Food and Drug Administration. FDA's Sentinel of Public Health: Field Staff Safeguards High Standards [Just the Facts Series, Publication No. FS 01-7]. Rockville, MD: Food and Drug Administration, December 2003.
- 21 USC §335b.
- 21 USC §333.
- 21 USC §332.
- See, The Federal Food, Drug, and Cosmetic Act. Available at http://www.usdoj.gov/civil/ocl/monograph/fdca.htm; accessed August 13, 2007; and OCL Client Agencies. Available at http://www.usdoj.gov/civil/ocl/client.htm; accessed August 17, 2007.
- See, 31 USC § 3730(b).
- See, Mikes v Straus, 274 F3d 687, 692 (2nd Cir 2001); Wikipedia. Qui tam. Available at http://en.wikipedia.org/wiki/Qui_tam; accessed August 15, 2007.
- See, e.g., In re: Pharmaceutical Industry Average Wholesale Price Litigation, — FSupp2d —, 2007 WL 2058731 (DMass July 17, 2007) (case under seal for 9 years); United States v Baylor University Medical Center, 469 F3d 263 (2nd Cir 2006) (case under seal for 8 years); Rost v Pfizer, 446 FSupp2d 6 (DMass 2006) (case under seal for almost 3 years); Franklin v Parke-Davis, 147 FSupp2d 39 (DMass 2001) (case under seal for 3 years).
- See, Taxpayers Against Fraud Education Fund. Whistleblowers help protect government from fraudulent drug manufacturers: False Claims Act recovers over $2.4 billion in Medicare and Medicaid fraud by drug companies. Available at http://www.taf.org/drugstudynov04.htm; accessed August 9, 2007.
- Klein DF, O'Brien CP. Improving detection of adverse effects of marketed drugs. JAMA 2007;298 (3): 333–334.
- McClellan M. Drug safety reform at the FDA—pendulum swing or systematic improvement? N Engl J Med 2007;356 (17): 1700–1702.
- Richard BJ. Drug safety: the 11th hour is now. Idaho Observer, March 2007. Available at http://proliberty.com/observer/20070301.htm; accessed July 25, 2007.
- Ray WA, Stein CM. Reform of drug regulation—beyond an independent drug-safety board. N Engl J Med 2006;354 (2): 194–201.
- Psaty BM, Burke SP. Protecting the health of the public—Institute of Medicine recommendations on drug safety. N Engl J Med 2006;355 (17): 1753–1755 (citing Drug Safety: Improvement Needed in FDA's Post-market Decision-making and Oversight Process [Report no. GAO-06-402]. Washington, DC: Government Accountability Office, March 2006).
- Avorn J. Paying for drug approvals—who's using whom? N Engl J Med 2007;356 (17): 1697–1700.
- Graham DJ. COX-2 inhibitors, other NSAIDs, and cardiovascular risk: the seduction of common sense. JAMA 2006;296 (13): 1653–1656.
- Congressional hearings on prescription drug safety could highlight “dissention” among FDA officials. Medical News Today, June 4, 2007. Available at http://www.medicalnewstoday.com/printerfriendlynews.php?newsid=72741; accessed August 13, 2007.
- Wood AJ, Stein CM, Woosley R. Making medicines safer—the need for an independent drug safety board. N Engl J Med 1998;339 (25): 1851–1854.
- Lenzer J. Secret US report surfaces on antidepressants in children. BMJ 2004;329 (7461): 307.
- Popeo DJ, Samp RA. Re: Office of Consumer Litigation oversight of criminal investigations into allegedly improper promotion of FDA-approved medical products [letter to James B. Comey, Deputy Attorney General, U.S. Department of Justice], March 24, 2005.
- Grassley C. Floor statements of Senator Grassley in opposition to the nomination of Dr. Andrew von Eschenbach to be FDA commissioner, December 7, 2006. Available at http://grassley.senate.gov/public/index.cfm?FuseAction=PressReleases.Detail&PressRelease_id=3af8c768-fb3a-4192-ae00-fafd617c39ca&Month=12&Year=2006; accessed October 24, 2007.
- Dart JR. Preemption issues and prescription drug litigation. Mealey's Litigation Report: Antidepressant Drugs, March 2005.
- Mitka M. Report criticizes lack of FDA oversight. JAMA 2006;296 (8): 920–922.
- Barron J. The FDA and government regulators. Available at http://www.jonbarron.org/newsletters/04/7-19-2004.php; accessed August 13, 2007.
- Committee on Oversight and Government Reform. Prescription for Harm: The Decline of FDA Enforcement Activity, June 2006. Available at http://oversight.house.gov/story.asp?ID=1074; accessed October 26, 2007.
- Dickinson JG. FDA enforcement actions loomed large in 2005. Medical Device & Diagnostic Industry, December 2005. Available at http://www.devicelink.com/mddi/archive/05/12/006.html; accessed August 13, 2007.
- Greenberg EF. Taking FDA's temperature in multiple ways. Packaging Digest, November 2005. Available at http://www.packagingdigest.com/articles/200511/22.php; accessed August 13, 2007.
- US Food and Drug Administration. Protecting the Public Health: FDA Pursues an Aggressive Enforcement Strategy [white paper], June 30, 2003. Available at http://www.fda.gov/oc/whitepapers/enforce.html; accessed August 13, 2007.
- Avorn J. Correspondence to Representative Henry Waxman, May 25, 2006. Available at http://oversight.house.gov/documents/20060626111957-56484.pdf; accessed October 26, 2007.
- Wilkes M. Correspondence to Congressman Henry Waxman, June 10, 2006. Available at http://oversight.house.gov/documents/20060626112038-10048.pdf; accessed October 26, 2007.
- Young SR. Correspondence to Congressman Henry Waxman, June 22, 2006. Available at http://oversight.house.gov/documents/20060626112240-73343.pdf; accessed October 26, 2007.
- Grassley C. Re: Union of Concerned Scientists Survey of FDA Scientists [memorandum to reporters and editors], July 20, 2006. Available at http://www.ucsusa.org/assets/documents/scientific_integrity/Grassley.pdf; accessed October 26, 2007.
- DeLauro RL. Union of Concerned Scientists report confirms FDA must restore “gold standard” [press release], July 20, 2006. Available at http://www.house.gov/delauro; accessed October 27, 2007.
- See, e.g., FDA's Regulation of the New Drug Versed, HR Rep No 1086, 100th Cong, 2nd Sess (1988); FDA's Regulation of the New Drug Merital, HR Rep No 206, 100th Cong, 1st Sess (1987); FDA's Regulation of Zomax, HR Rep No 584, 98th Cong, 1st Sess (1983); Deficiencies in FDA's Regulation of the New Drug “Oraflex,” HR Rep No 511, 98th Cong, 1st Sess (1983).
- Moynihan R. Alosetron: a case study in regulatory capture, or a victory for patients' rights? BMJ 2002;325 (7364): 592–595.
- Avorn J. Dangerous deception—hiding the evidence of adverse drug effects. N Engl J Med 2006;355 (21): 2169–2171.
- Hiatt WR. Observational studies of drug safety—aprotinin and the absence of transparency. N Engl J Med 2006;355 (21): 2171–2173.
- Ross DB. The FDA and the case of Ketek. N Engl J Med 2007;356 (16): 1601–1604.
- Jacobson PD, Parmet WE. A new era of unapproved drugs: the case of Abigail Alliance v Von Eschenbach. JAMA 2007;297 (2): 205–208.
- Topol EJ. Failing the public health—rofecoxib, Merck, and the FDA. N Engl J Med 2004;351 (17): 1707–1709.
- Eisenberg RS. Learning the value of drugs—is rofecoxib a regulatory success story? N Engl J Med 2005;352 (13): 1285–1287.
- Willman D. Hidden risks, lethal truths; Warner-Lambert won approval for Rezulin after masking the scope of liver injuries in clinical studies. Los Angeles Times, June 30, 2002.
- Lurie P, Almeida CM, Stine N, Stine AR, Wolfe SM. Financial conflict of interest disclosure and voting patterns at Food and Drug Administration drug advisory committee meetings. JAMA 2006;295 (16): 1921–1928.
- Johnson E. Ghostwriting: the basics. CBC News, March 25, 2003. Available at http://www.cbc.ca/consumers/market/files/health/ghostwriting/faq.html; accessed October 29, 2007. Attkisson S. Ghostwriting articles for medical journals. CBS News, April 5, 2001. Available at http://www.cbsnews.com/stories/2002/01/31/health/printable327012.shtml; accessed October 29, 2007.
- Donohue JM, Cevasco M, Rosenthal MB. A decade of direct-to-consumer advertising of prescription drugs. N Engl J Med 2007;357 (7): 673–681.
- Psaty BM, Furberg CD, Ray WA, Weiss NS. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis. JAMA 2004;292 (21): 2622–2631.
- Pringle E. Criminal prosecution of Lilly sought over Zyprexa. Online Journal, January 5, 2007. Available at http://onlinejournal.com/artman/publish/printer_1605.shtml; accessed August 13, 2007.
- Ohler v Purdue Pharma, LP, 2002 WL 88945 (EDLa Jan 22, 2002), citing, 63 FedReg 66383–66384.
- Perry v Novartis Pharma Corp, 456 FSupp2d 678, 687 (ED Pa 2006), citing, Harris G. Study condemns F.D.A.'s handling of drug safety. New York Times, September 23, 2006.
- Kesselheim AS, Avorn J. The role of litigation in defining drug risks. JAMA 2007;297 (3): 308–311.
- Alliance for Human Research Protection. GSK reverses decade of denial: Paxil triggered suicide in adults [press release], May 12, 2006. Available at http://www.ahrp.org/cms/content/view/166/28/; accessed August 14, 2007.
- US Food and Drug Administration. Drug maker to pay $430 million in fines, civil damages. FDA Consumer Magazine, July–August 2004. Available at http://www.fda.gov/fdac/features/2004/404_wl.html; accessed August 13, 2007.
- The United States Attorney's Office, Western District of Virginia. The Purdue Frederick Company, Inc. and top executives plead guilty to misbranding OxyContin; will pay over $600 million [press release], May 10, 2007. Available at http://www.usdoj.gov/usao/vaw/press_releases/purdue_frederick_10may2007.html; accessed July 20, 2007.
- Office of the Attorney General, Commonwealth of Virginia. McDonnell, Brownlee announce maker of OxyContin pleads guilty to felony misbranding [press release], May 10, 2007. Available at http://www.oag.state.va.us/press_releases/NewsArchive/051007_OxyContin.html; accessed July 20, 2007.
- Waxman HA. Statement of Rep. Henry A. Waxman for the hearing, “The Roles of FDA and Pharmaceutical Companies in Ensuring the Safety of Approved Drugs, Like Vioxx,” May 5, 2005. Available at http://oversight.house.gov/documents/20050505113149-41995.pdf; accessed October 29, 2007.
- Waxman HA. Re: The Marketing of Vioxx to physicians [memorandum to Democratic members of the Government Reform Committee], May 5, 2005. Available at http://oversight.house.gov/documents/20050505114932-41272.pdf; accessed October 29, 2007.
- US Food and Drug Administration. Renewed legislation improves safety of FDA-regulated products—frequently asked questions [Consumer Update], September 27, 2007. Available at http://www.fda.gov/consumer/updates/legislation092707.html; accessed October 3, 2007.
- Curfman GD, Morrissey S, Drazen JM. Safer drugs for the American people. N Engl J Med 2007;357 (6): 602–603.
- Hampton T. Views on the FDA. JAMA 2007;295 (24): 2839.
- Lee KA. Senator accuses FDA nominee of withholding information. Congress Daily, December 1, 2006. Available at http://www.govexec.com/story_page_pf.cfm?articleid=35591&printerfriendlyvers=1; accessed October 29, 2007.
- Avorn J. Keeping science on top in drug evaluation. N Engl J Med 2007;357 (7): 633–635.
Free access
Preemption, Tort Reform, and Pharmaceutical Claims, Part Two: Has the Food and Drug Administration Shown It Is Solely Responsible for the Protection of Patients? Can It Do So? Will It Do So?
Reprints and Corporate Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Academic Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.